PGNY
Progyny, Inc. [PGNY] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
PGNY Stock Summary
Top PGNY Correlated Resources
PGNY
Top 10 Correlated ETFs
PGNY
Top 10 Correlated Stocks
PGNY
In the News
PGNY Financial details
Company Rating
Strong Buy
Market Cap
3.3B
Income
62.04M
Revenue
1.09B
Book val./share
5.77
Cash/share
3.87
Dividend
-
Dividend %
-
Employees
563
Optionable
No
Shortable
Yes
Earnings
06 May 2024
P/E
69.27
Forward P/E
-
PEG
6.93
P/S
3.5
P/B
6.99
P/C
8.37
P/FCF
18.16
Quick Ratio
3.12
Current Ratio
3.16
Debt / Equity
0.04
LT Debt / Equity
0.03
-
-
EPS (TTM)
0.66
EPS next Y
-
EPS next Q
-
EPS this Y
96.97%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
NAN%
Revenue last 5Y
36.5%
Revenue Q/Q
-3.9%
EPS Q/Q
-17.65%
-
-
-
-
SMA20
-8.33%
SMA50
-15.38%
SMA100
-
Inst Own
75.24%
Inst Trans
0.78%
ROA
7%
ROE
12%
ROC
0.1%
Gross Margin
22%
Oper. Margin
5%
Profit Margin
5%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
29.44-44.95
52W High
-26.34%
52W Low
+11.76%
RSI
29
Rel Volume
0.95
Avg Volume
816.51K
Volume
773.01K
Perf Week
-7.32%
Perf Month
-8.68%
Perf Quarter
6.3%
Perf Half Y
-1.49%
-
-
-
-
Beta
1.475
-
-
Volatility
0.85%, 1.65%
Prev Close
1.66%
Price
32.41
Change
-0.86%
PGNY Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 2.75 | 4.02 | 5.62 | 8.54 | 11.46 | |
| Net income per share | -0.1 | 0.54 | 0.74 | 0.33 | 0.65 | |
| Operating cash flow per share | -0.02 | 0.42 | 0.29 | 0.87 | 1.99 | |
| Free cash flow per share | -0.05 | 0.41 | 0.27 | 0.84 | 1.95 | |
| Cash per share | 0.96 | 1.28 | 1.34 | 2.05 | 3.91 | |
| Book value per share | 1.37 | 1.95 | 2.83 | 4.09 | 5.82 | |
| Tangible book value per share | 1.2 | 1.79 | 2.69 | 3.96 | 5.7 | |
| Share holders equity per share | 1.37 | 1.95 | 2.83 | 4.09 | 5.82 | |
| Interest debt per share | -0.01 | 0.11 | 0.1 | 0.09 | 0.2 | |
| Market cap | 2.29B | 3.63B | 4.49B | 2.87B | 3.53B | |
| Enterprise value | 2.21B | 3.57B | 4.4B | 2.76B | 3.45B | |
| P/E ratio | -267.72 | 78.21 | 68.22 | 94.6 | 56.95 | |
| Price to sales ratio | 9.99 | 10.54 | 8.96 | 3.65 | 3.25 | |
| POCF ratio | -1.5K | 100.37 | 172.31 | 35.72 | 18.71 | |
| PFCF ratio | -510.93 | 103.33 | 187.66 | 37.22 | 19.08 | |
| P/B Ratio | 20.08 | 21.77 | 17.82 | 7.62 | 6.38 | |
| PTB ratio | 20.08 | 21.77 | 17.82 | 7.62 | 6.38 | |
| EV to sales | 9.64 | 10.36 | 8.79 | 3.51 | 3.17 | |
| Enterprise value over EBITDA | 73.82 | 348.33 | 130.87 | 110.64 | 53.59 | |
| EV to operating cash flow | -1.44K | 98.66 | 169.09 | 34.32 | 18.3 | |
| EV to free cash flow | -493.02 | 101.57 | 184.14 | 35.77 | 18.66 | |
| Earnings yield | 0 | 0.01 | 0.01 | 0.01 | 0.02 | |
| Free cash flow yield | 0 | 0.01 | 0.01 | 0.03 | 0.05 | |
| Debt to equity | 0 | 0.06 | 0.03 | 0.02 | 0.04 | |
| Debt to assets | 0 | 0.04 | 0.02 | 0.01 | 0.03 | |
| Net debt to EBITDA | -2.68 | -6.05 | -2.5 | -4.51 | -1.21 | |
| Current ratio | 3.66 | 2.45 | 2.62 | 2.72 | 3.44 | |
| Interest coverage | -56.04 | 68.99 | 70.15 | 28.67 | 0 | |
| Income quality | 0.18 | 0.78 | 0.4 | 2.65 | 3.04 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.1 | 0.14 | 0.12 | 0.12 | 0.11 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.09 | 0.05 | 0.03 | 0.02 | 0.02 | |
| Capex to operating cash flow | 1.93 | -0.03 | -0.08 | -0.04 | -0.02 | |
| Capex to revenue | -0.01 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | -1.39 | -0.54 | -1.64 | -2.02 | -1.6 | |
| Stock based compensation to revenue | 0.02 | 0.04 | 0.07 | 0.13 | 0.11 | |
| Graham number | 1.78 | 4.87 | 6.85 | 5.5 | 9.25 | |
| ROIC | 0.24 | 0.24 | 0.24 | 0.07 | 0.09 | |
| Return on tangible assets | -0.06 | 0.19 | 0.19 | 0.06 | 0.08 | |
| Graham Net | 0.95 | 0.92 | 1.28 | 2.21 | 3.68 | |
| Working capital | 96.28M | 112.44M | 159.72M | 274.32M | 454.46M | |
| Tangible asset value | 100.02M | 153.85M | 239.34M | 364.99M | 541.55M | |
| Net current asset value | 96.28M | 103.24M | 152.3M | 267.84M | 437.22M | |
| Invested capital | 0 | 0.06 | 0.03 | 0.02 | 0.04 | |
| Average receivables | 35.19M | 61.36M | 105.11M | 187.31M | 240.97M | |
| Average payables | 17.48M | 31.45M | 52.46M | 85.34M | 117.36M | |
| Average inventory | 0 | 0 | 0.5 | 0.5 | 0 | |
| Days sales outstanding | 74.78 | 80.08 | 98.1 | 111.35 | 81.1 | |
| Days payables outstanding | 38.42 | 57.8 | 57.69 | 64.38 | 53.87 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 4.88 | 4.56 | 3.72 | 3.28 | 4.5 | |
| Payables turnover | 9.5 | 6.32 | 6.33 | 5.67 | 6.78 | |
| Inventory turnover | 0 | 0 | 388.49M | 0 | 0 | |
| ROE | -0.07 | 0.28 | 0.26 | 0.08 | 0.11 | |
| Capex per share | -0.04 | -0.01 | -0.02 | -0.04 | -0.04 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 2.3 | 2.75 | 2.95 | 2.94 | 2.81 | |
| Net income per share | 0.04 | 0.19 | 0.16 | 0.17 | 0.14 | |
| Operating cash flow per share | 0.55 | 0.22 | 0.8 | 0.57 | 0.39 | |
| Free cash flow per share | 0.55 | 0.21 | 0.79 | 0.56 | 0.39 | |
| Cash per share | 2.03 | 2.22 | 2.98 | 3.51 | 3.87 | |
| Book value per share | 4.05 | 4.52 | 4.96 | 5.4 | 5.77 | |
| Tangible book value per share | 3.92 | 4.4 | 4.83 | 5.27 | 5.64 | |
| Share holders equity per share | 4.05 | 4.52 | 4.96 | 5.4 | 5.77 | |
| Interest debt per share | 0.09 | 0.2 | 0.21 | 0.2 | 0.2 | |
| Market cap | 2.9B | 3.01B | 3.73B | 3.25B | 3.57B | |
| Enterprise value | 2.79B | 2.88B | 3.57B | 3.11B | 3.49B | |
| P/E ratio | 212.64 | 42.62 | 62.15 | 51.09 | 66.23 | |
| Price to sales ratio | 13.53 | 11.66 | 13.34 | 11.57 | 13.22 | |
| POCF ratio | 56.27 | 143.79 | 49.03 | 59.96 | 94.76 | |
| PFCF ratio | 57.07 | 152.91 | 49.53 | 61.04 | 96.5 | |
| P/B Ratio | 7.69 | 7.1 | 7.94 | 6.3 | 6.45 | |
| PTB ratio | 7.69 | 7.1 | 7.94 | 6.3 | 6.45 | |
| EV to sales | 13 | 11.13 | 12.8 | 11.07 | 12.93 | |
| Enterprise value over EBITDA | 742.63 | 185 | 227.52 | 165.63 | 252.95 | |
| EV to operating cash flow | 54.09 | 137.26 | 47.03 | 57.37 | 92.69 | |
| EV to free cash flow | 54.85 | 145.97 | 47.5 | 58.4 | 94.4 | |
| Earnings yield | 0 | 0.01 | 0 | 0 | 0 | |
| Free cash flow yield | 0.02 | 0.01 | 0.02 | 0.02 | 0.01 | |
| Debt to equity | 0.02 | 0.05 | 0.04 | 0.04 | 0.04 | |
| Debt to assets | 0.01 | 0.03 | 0.03 | 0.03 | 0.03 | |
| Net debt to EBITDA | -29.95 | -8.8 | -9.7 | -7.48 | -5.65 | |
| Current ratio | 2.72 | 2.55 | 2.89 | 3.16 | 3.44 | |
| Interest coverage | 5.9 | -11.37 | 0 | 0 | 0 | |
| Income quality | 15.12 | 1.19 | 5.07 | 3.41 | 2.8 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.13 | 0.11 | 0.11 | 0.11 | 0.1 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | |
| Capex to operating cash flow | -0.01 | -0.06 | -0.01 | -0.02 | -0.02 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | -1.62 | -2.31 | -1.44 | -1.65 | -1.07 | |
| Stock based compensation to revenue | 0.14 | 0.12 | 0.11 | 0.11 | 0.11 | |
| Graham number | 1.83 | 4.38 | 4.2 | 4.5 | 4.27 | |
| ROIC | 0.01 | 0.04 | 0.03 | 0.03 | 0.02 | |
| Return on tangible assets | 0.01 | 0.03 | 0.02 | 0.02 | 0.02 | |
| Graham Net | 2.19 | 2.32 | 2.84 | 3.41 | 3.64 | |
| Working capital | 274.32M | 320.21M | 367.23M | 417.85M | 454.46M | |
| Tangible asset value | 364.99M | 412.52M | 457.62M | 503.51M | 541.55M | |
| Net current asset value | 267.84M | 301.76M | 349.09M | 400.15M | 437.22M | |
| Invested capital | 0.02 | 0.05 | 0.04 | 0.04 | 0.04 | |
| Average receivables | 249.05M | 276.66M | 289.1M | 266.86M | 255.32M | |
| Average payables | 106.73M | 127.46M | 137.89M | 131.1M | 128.73M | |
| Average inventory | 0.5 | 0 | 0.5 | 0.5 | 0 | |
| Days sales outstanding | 100.81 | 109.1 | 85.36 | 86.12 | 80.64 | |
| Days payables outstanding | 57.92 | 65.61 | 53.56 | 54.45 | 52.99 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0.89 | 0.82 | 1.05 | 1.05 | 1.12 | |
| Payables turnover | 1.55 | 1.37 | 1.68 | 1.65 | 1.7 | |
| Inventory turnover | 0 | 0 | 218.73M | 0 | 0 | |
| ROE | 0.01 | 0.04 | 0.03 | 0.03 | 0.02 | |
| Capex per share | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
PGNY Frequently Asked Questions
What is Progyny, Inc. stock symbol ?
Progyny, Inc. is a US stock , located in New york of Ny and trading under the symbol PGNY
What is Progyny, Inc. stock quote today ?
Progyny, Inc. stock price is $32.41 today.
Is Progyny, Inc. stock public?
Yes, Progyny, Inc. is a publicly traded company.
Company Profile
- Volume Average 816.51K
- Market Capitalization 3.3B
- Employee 563
- CEO Mr. Peter Anevski
- Headquarters New York,NY,US
- IPO Date 2019-10-25
-
Website
https://www.progyny.com 
Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimbursement programs for employers. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
